EUCTR2021-001577-24-ES进行中（未招募）1 期
A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still’s disease (including systemic juvenile idiopathic arthritis and Adult onset Still’s disease) or with MAS in Systemic lupus erythematous - NI-0501-14
Swedish Orphan Biovitrum AG (Sobi AG)0 个研究点目标入组 41 人开始时间: 2021年8月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Run-in phase in all cohorts
- •1. Informed consent provided by the subject or by the subject's legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as required by local law.
- •2. Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of MAS.
- •3. MAS defined as per the criteria defined below for each cohort and requiring treatment with GCs.
- •Interventional phase in all cohorts
- •1. Informed consent provided by the subject or by the subject’s legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as as required by local law.
- •2. Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of active MAS.
- •3. Subjects who have shown an inadequate response to high dose intravenous (i.v.) GCs administered for at least 3 days according to local standard clinical practice, including but not limited to pulses of 30 mg/kg PDN on 3 consecutive days. High i.v. GCs dose is recommended not to be lower than 2 mg/kg/ day PDN equivalent (or at least 60 mg/day in pediatric subjects of 30 kg or more, and at least 1g/day in adult MAS subjects). In case of rapid worsening of the subject’s condition and/or laboratory parameters, as per Investigator judgment, inclusion may occur within less than 3 days from starting high dose GCs.
- •4. Diagnosis of active MAS confirmed by the treating rheumatologist, having ascertained the followings:
- •a. Febrile subjects presenting with ferritin > 684 ng/mL.
- •b. and any 2 of:
- •i. Platelet count = 181 x109/L
- •ii. AST-level > 48 U/L
- •iii. Triglycerides > 156 mg/dL
- •iv. Fibrinogen level = 360 mg/dL
- •5. Female subjects of child-bearing potential willing to use highly effective methods of contraception from study drug initiation to 6 months after the last dose of study drug.
- •Specific inclusion criteria to Cohort 1 and Cohort 2
- •6. Cohort 1:
- •a. Confirmed sJIA diagnosis. For subjects presenting with MAS in the context of the onset of sJIA, high presumption of sJIA will suffice for eligibility.
- •b. Confirmed diagnosis of AOSD as per Yamaguchi criteria.
- •7. Cohort 2:
- •a. Confirmed diagnosis of SLE as per SLICC’12 criteria.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 22
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •1. Primary HLH documented by either the presence of a known causative genetic mutation or abnormal perforin expression and CD107a degranulation assay as described with primary hemophagocytic lymphohistiocytosis or by the presence of family history.
- •2. Confirmed malignancy. Note: subjects with a suspected malignancy should have mononuclaear cells typed by flow cytometry and/or tissue biopsy, as applicable, to rule out malignancy.
- •3. Treatment with canakinumab, JAK inhibitors, TNF inhibitors and tocilizumab at the time of emapalumab initiation.
- •4. Ongoing treatment with anakinra at a dose above 4 mg/kg at time of emapalumab initiation.
- •5. Subjects treated with etoposide for MAS in the last 1 month.
- •6. Clinically active mycobacteria (typical and atypical), Histoplasma Capsulatum, or Salmonella infections.
- •7. Evidence of leishmania infections.
- •8. Evidence of latent tuberculosis.
- •9. History of hypersensitivity or allergy to any component of the study drug.
- •10. Receipt of a Bacillus Calmette-Guerin (BCG) vaccine within 12 weeks prior to screening.
- •11. Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screening.
- •12. Pregnancy or lactating female subjects.
研究者
相似试验
招募中
2 期
A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still*s disease (including systemic juvenile idiopathic arthritis and Adult onset Still*s disease) or with MAS in Systemic lupus erythematousMASNL-OMON52297Swedish Orphan International5
已完成
3 期
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics of emapalumab in children and adults with macrophage activation syndrome (MAS)2024-516153-52-00Swedish Orphan Biovitrum AG15
进行中（未招募）
1 期
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS)EUCTR2021-001577-24-FRSwedish Orphan Biovitrum AG (Sobi AG)41
进行中（未招募）
1 期
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS)EUCTR2021-001577-24-PLSwedish Orphan Biovitrum AG (Sobi AG)41
招募中
1 期
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS)Macrophage activation syndrome (MAS) in the context of Systemic juvenile inflammatory arthritis (sJIA) and Adult onset Still’s disease (AOSD).MAS in the context of pediatric and adult Systemic lupus erythematous (SLE).MedDRA version: 21.1Level: PTClassification code 10071583Term: Haemophagocytic lymphohistiocytosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2021-001577-24-DESwedish Orphan Biovitrum AG (Sobi AG)41